These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 37834269

  • 1. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer.
    Luo L, Sun X, Yang Y, Xia L, Wang S, Fu Y, Zhu Y, Xu S, Zhu W.
    Int J Mol Sci; 2023 Oct 01; 24(19):. PubMed ID: 37834269
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov 01; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y, Sun X, Luo L, Peng R, Yang R, Cheng Z, Lv Y, Li H, Tang Q, Zhu W, Qiao D, Xu S.
    Arch Pharm (Weinheim); 2023 Dec 01; 356(12):e2300403. PubMed ID: 37840368
    [Abstract] [Full Text] [Related]

  • 5. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH.
    Cells; 2021 Oct 27; 10(11):. PubMed ID: 34831139
    [Abstract] [Full Text] [Related]

  • 6. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    Neoplasia; 2014 Jan 27; 16(1):43-72. PubMed ID: 24563619
    [Abstract] [Full Text] [Related]

  • 7. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.
    Clin Cancer Res; 2014 Jul 01; 20(13):3507-20. PubMed ID: 24879796
    [Abstract] [Full Text] [Related]

  • 8. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
    Mardanshahi A, Gharibkandi NA, Vaseghi S, Abedi SM, Molavipordanjani S.
    Mol Biol Rep; 2021 Aug 01; 48(8):1-14. PubMed ID: 34357550
    [Abstract] [Full Text] [Related]

  • 9. PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.
    Altundag K.
    Med Oncol; 2024 Oct 14; 41(11):279. PubMed ID: 39400749
    [No Abstract] [Full Text] [Related]

  • 10. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
    Zhang L, Zheng Y, Zeng L, Zhang F, Che D, Cao Z, Huang C, Xian L, Zhang X, Zhang H, Guo Z.
    Life Sci; 2021 Nov 15; 285():119995. PubMed ID: 34592228
    [Abstract] [Full Text] [Related]

  • 11. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
    Aggarwal S, John S, Sapra L, Sharma SC, Das SN.
    Cancer Chemother Pharmacol; 2019 Mar 15; 83(3):451-461. PubMed ID: 30519710
    [Abstract] [Full Text] [Related]

  • 12. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
    Wang S, Zhang Y, Ren T, Wu Q, Lu H, Qin X, Liu Y, Ding H, Zhao Q.
    Cell Death Dis; 2020 Jun 30; 11(6):491. PubMed ID: 32606352
    [Abstract] [Full Text] [Related]

  • 13. Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging.
    Altine B, Gai Y, Han N, Jiang Y, Ji H, Fang H, Niyonkuru A, Bakari KH, Rajab Arnous MM, Liu Q, Zhang Y, Lan X.
    Mol Pharm; 2019 Nov 04; 16(11):4563-4571. PubMed ID: 31553879
    [Abstract] [Full Text] [Related]

  • 14. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells.
    Omeljaniuk WJ, Krętowski R, Ratajczak-Wrona W, Jabłońska E, Cechowska-Pasko M.
    Int J Mol Sci; 2021 Oct 26; 22(21):. PubMed ID: 34768941
    [Abstract] [Full Text] [Related]

  • 15. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X, Xia M, Wang J, Yu H, Chai J, Zhang Z, Sun Y, Su J, Sun L.
    Biomed Pharmacother; 2020 Sep 26; 129():110397. PubMed ID: 32585451
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Sep 26; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 17. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 26; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 18. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo.
    Yang J, Liu Y, Lan S, Yu S, Ma X, Luo D, Shan H, Zhong X, Yan G, Li R.
    J Med Chem; 2022 Oct 13; 65(19):12781-12801. PubMed ID: 36191148
    [Abstract] [Full Text] [Related]

  • 19. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
    Zhang H, Xu HL, Wang YC, Lu ZY, Yu XF, Sui DY.
    Int J Mol Sci; 2018 Apr 02; 19(4):. PubMed ID: 29614812
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S, Luo L, Sun X, Yang Y, Guo Q, Jiang Z, Wu Y.
    Bioorg Med Chem; 2023 Jan 15; 78():117133. PubMed ID: 36599263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.